“L’Aquila’s plant is my family's biggest investment” says Sergio Dompé, Executive President of Dompé farmaceutici. It was July 21st, 1993 when the facility in Via Campo di Pile opened its doors for its inauguration hosting, among others, Italian President Oscar Luigi Scalfaro and Nobel for Medicine Rita Levi Montalcini. “30 years have gone by and I want to reiterate my gratitude to the people who day contribute in making this facility better and more competitive - continues Dompé - we owe it the dedication of our workers if this company has developed in what today is perceived as one of the most innovative facilities in Europe and in the world”.

Originally focused on the production of Primary Care drugs, the hub evolved to match the demands of the market and expanding its biotech area.

Currently, the plant houses two separate production areas: one dedicated to the production, control, and distribution of traditional drugs (Primary & Specialty care), and another dedicated to the development, production, control, and distribution of recombinant proteins, including NGF, the active ingredient at the base of the FDA approved product for the USA market, which Dompé entered in 2017.

The 1.830.000 square feet of the plant host the manufacturing of 700 million doses annually, along with over 1,500 tons of granules, 925 thousand gallons of oral liquids, resulting in a total of 46 million packages distributed in over 23 countries worldwide.

In 2023 the site counts over 300 employees, of whom 40% are women and 48% are graduates.

“The respect for the environment and the territory is at the core of our values - emphasizes Chief Industrial Officer Stefano Arena - Today the company is investing in the reduction of its environmental impact by improving existing systems and installing new high-performance technologies to reduce energy consumption. In 2023, the installation of a state-of-the-art trigeneration plant will be completed, capable of self-generating 70% of the site's energy needs and reducing CO2 emissions."